<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04254549</url>
  </required_header>
  <id_info>
    <org_study_id>19-002908</org_study_id>
    <nct_id>NCT04254549</nct_id>
  </id_info>
  <brief_title>Rifaximin in Patients With Diabetic Gastroparesis</brief_title>
  <official_title>Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of
      bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">September 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in bloating</measure>
    <time_frame>Week 2, week 4, week 8</time_frame>
    <description>Change is the self reported bloating questionnaire comprised of 45 questions addressing symptoms of bloating/distention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Diabetic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Intervention Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects diagnosed with gastroparesis will receive Rifaximin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects diagnosed with gastroparesis will receive a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>550 mg by mouth three times daily for 14 days</description>
    <arm_group_label>Intervention Treatment</arm_group_label>
    <other_name>TD-1473</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>By mouth three times daily for 14 days</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Men and women adult patients, aged 18-75, with diabetic gastroparesis

          -  Diagnosis of diabetic gastroparesis will have been made previously using a combination
             of symptoms (e.g., nausea, vomiting, bloating, early satiety, abdominal pain), the
             absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid
             phase scintigraphic study (GES; &gt; 20% remaining at 4 hours)

        Exclusion Criteria

          -  Prior surgery to the stomach or esophagus

          -  Known mechanical obstruction of the GI tract

          -  Current or recent (&lt; 4 weeks) use of opioids

          -  Current/active use of cannabis

          -  Current or recent (&lt; 4 weeks) use of antibiotics

          -  Current or recent use of antifungal agents (&lt; 4 weeks)

          -  Prior treatment with rifaximin (&lt; 1 year)

          -  Uncontrolled diabetes with a HgbA1c &gt; 12

          -  Severe uncontrolled or untreated anxiety or depression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian E Lacy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Lacy, MD</last_name>
      <phone>904-953-2000</phone>
      <email>lacy.brian@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cangemi David, MD</last_name>
      <phone>904-953-2000</phone>
      <email>cangemi.david@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Brian E. Lacy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

